Prezentacija prvog srpskog udruzenja priredjivaca igara na srecu JAKTA iz 2008. godine.
JAKTA presentation, first serbian trade association for games of chance in Serbia 2008
JAKTA ON-LINE KOCKA - REGULATIVA U EU, MR. DUSAN PAVLOVIC, 2012Mirjana Acimovic
Direktiva 2000/31 (Direktiva elektronske trgovine) – isključuje kockanje iz svog obima regulusanja
Direktiva 2010/12 (Direktiva o pružanju audio-vizuelnih usluga) - isključuje kockanje iz svog obima regulusanja sa izuzetkom
Direktiva 2005/29 (nelojalna poslovna praksa) – primenjuje se u potpunosti
Direktiva 2005/60 (borba protiv pranja novca) – primenjuje se u potpunosti
JAKTA - EUROMAT MR Helmut Kafka-presentation at Jakta V Gaming Congress-22 oc...Mirjana Acimovic
JAKTA’s 5th Gaming Congress
Summarising the situation in Europe
- EUROMAT’s perspective -
Belgrade, 22 October 2012
Helmut Kafka, Vice-President, EUROMAT
BMM Compliance is a global gaming certification laboratory that has been testing gaming devices and systems for 30 years. It has offices in 10 locations around the world and 240 employees. The document discusses BMM's regulatory services for gaming regulators, manufacturer services for gaming manufacturers, and operator services for gaming operators. It provides details on the various testing, auditing, consulting and compliance services offered by BMM to support the gaming industry.
JAKTA ASSOCIATION AT EAST EUROPEAN GAMING SUMMIT 2011Mirjana Acimovic
The document summarizes facts about Serbia's gaming market and law. It notes that Serbia has 17,000 slot machines, 1,700 slot clubs, 1,240 betting shops, and 2 casinos. A new gambling law is being considered in parliament that key gaming representatives hope will adopt stricter regulations, ensure equal conditions and protection of players/minors, establish technical standards with a gaming laboratory, and protect intellectual property.
JAKTA is the Association of Gaming Organizers, Authorized Servicers and Producers of Gaming Equipment founded in 2005 in Serbia. In 2009, JAKTA became an official member of EUROMAT. JAKTA's goals are to provide better conditions for gaming operations in Serbia, raise industry standards, and cooperate with the Serbian government and institutions to benefit players and gaming companies while preventing pathological gambling. For its members, JAKTA provides legal assistance, verified industry information, technical support, business consulting, and help starting gaming businesses.
JAKTA ON-LINE KOCKA - REGULATIVA U EU, MR. DUSAN PAVLOVIC, 2012Mirjana Acimovic
Direktiva 2000/31 (Direktiva elektronske trgovine) – isključuje kockanje iz svog obima regulusanja
Direktiva 2010/12 (Direktiva o pružanju audio-vizuelnih usluga) - isključuje kockanje iz svog obima regulusanja sa izuzetkom
Direktiva 2005/29 (nelojalna poslovna praksa) – primenjuje se u potpunosti
Direktiva 2005/60 (borba protiv pranja novca) – primenjuje se u potpunosti
JAKTA - EUROMAT MR Helmut Kafka-presentation at Jakta V Gaming Congress-22 oc...Mirjana Acimovic
JAKTA’s 5th Gaming Congress
Summarising the situation in Europe
- EUROMAT’s perspective -
Belgrade, 22 October 2012
Helmut Kafka, Vice-President, EUROMAT
BMM Compliance is a global gaming certification laboratory that has been testing gaming devices and systems for 30 years. It has offices in 10 locations around the world and 240 employees. The document discusses BMM's regulatory services for gaming regulators, manufacturer services for gaming manufacturers, and operator services for gaming operators. It provides details on the various testing, auditing, consulting and compliance services offered by BMM to support the gaming industry.
JAKTA ASSOCIATION AT EAST EUROPEAN GAMING SUMMIT 2011Mirjana Acimovic
The document summarizes facts about Serbia's gaming market and law. It notes that Serbia has 17,000 slot machines, 1,700 slot clubs, 1,240 betting shops, and 2 casinos. A new gambling law is being considered in parliament that key gaming representatives hope will adopt stricter regulations, ensure equal conditions and protection of players/minors, establish technical standards with a gaming laboratory, and protect intellectual property.
JAKTA is the Association of Gaming Organizers, Authorized Servicers and Producers of Gaming Equipment founded in 2005 in Serbia. In 2009, JAKTA became an official member of EUROMAT. JAKTA's goals are to provide better conditions for gaming operations in Serbia, raise industry standards, and cooperate with the Serbian government and institutions to benefit players and gaming companies while preventing pathological gambling. For its members, JAKTA provides legal assistance, verified industry information, technical support, business consulting, and help starting gaming businesses.
The gaming and amusement industry can contribute by making industry data available to public authorities and in many cases the industry also directly funds research into problem behaviour; however, as governments derive substantial tax revenues from the industry, and this trend is increasing, EUROMAT and its members see a clear case for a greater proportion of this revenue to directly fund the development of a body of credible evidence.
Clinical research involves investigating medical treatments and devices with human subjects to determine safety and effectiveness, and can include clinical trials, mechanisms of disease, and outcomes research. A sponsor initiates and finances clinical trials and is responsible for selecting qualified investigators, while investigators ensure ethical conduct of the trial and respect for subjects. Clinical research associates support investigators and sponsors in carrying out clinical trials.
This document discusses concepts of in-vitro screening as an alternative to animal testing. It describes some of the major alternatives like cell culture techniques and computer simulation that aim to replace, reduce or refine animal testing. Specifically, it provides examples of how cell cultures have been developed as alternatives for tasks like monoclonal antibody production and toxicity testing. It also discusses the "Three Rs" framework of replacing, reducing and refining animal use in testing.
This document discusses translational pharmacology, which aims to translate biomedical research findings into improved patient care and treatment. It involves applying laboratory research to clinical practice through a "bench to bedside" approach. The objectives of translational pharmacology are to discover disease origins and biomarkers, and develop new diagnostics and therapies more quickly. While powerful tools now exist, hurdles remain, including scientific, ethical, regulatory, financial and lack of investigators. Translational pharmacology seeks to bridge specialized fields and provide better pre-clinical results and dosing regimens to maximize patient benefit.
Peptic ulcer disease and GERD are common digestive disorders caused by an imbalance between gastric acid and the stomach's protective mechanisms. Peptic ulcers form when the stomach or duodenal lining is broken down, typically due to H. pylori infection or long-term NSAID use. GERD occurs when stomach acid backs up into the esophagus, often due to a weak lower esophageal sphincter. Both are treated using proton pump inhibitors to reduce acid production along with antibiotics for H. pylori if present. Lifestyle changes like sleeping upright and smaller meals can help prevent acid reflux.
Cell lines are permanently established cell cultures that can proliferate indefinitely. They are derived from primary cell cultures which have a finite lifespan. Continuous cell lines have undergone transformation to proliferate indefinitely, unlike finite primary cultures. Common types of cell lines include normal and transformed cell lines of epithelial, fibroblast, or lymphoblast morphology derived from human or animal tissues. Primary cultures are used to establish cell lines which are then used for applications like drug screening, toxicity testing, and cancer research.
This document outlines the phases of clinical trials, from Phase 0 to Phase IV. It defines clinical trials as prospective biomedical studies on human subjects to answer questions about interventions. The objectives are listed as diagnosing or treating disease, preventing disease or early death, or changing behaviors. The phases are described in order from exploratory studies in small groups in Phase 0 to post-marketing surveillance trials in large populations in Phase IV. The importance of clinical trials is that they follow strict scientific standards to protect patients and produce reliable results, as a final stage of research after laboratory and animal testing.
This document discusses high throughput screening and cell-based assays. It begins by defining high throughput screening as a process used in drug discovery to quickly assay a large number of compounds against a biological target to identify hits or leads. It then describes some key aspects of high throughput screening methodology including detection methods like spectroscopy, chromatography, and microscopy. The document outlines the advantages of cell-based assays compared to biochemical assays, noting they provide a more accurate representation using live cells. Finally, it defines the key elements of a cell-based assay as having a cellular component, a target molecule, an instrument, and informatics for data analysis.
The gaming and amusement industry can contribute by making industry data available to public authorities and in many cases the industry also directly funds research into problem behaviour; however, as governments derive substantial tax revenues from the industry, and this trend is increasing, EUROMAT and its members see a clear case for a greater proportion of this revenue to directly fund the development of a body of credible evidence.
Clinical research involves investigating medical treatments and devices with human subjects to determine safety and effectiveness, and can include clinical trials, mechanisms of disease, and outcomes research. A sponsor initiates and finances clinical trials and is responsible for selecting qualified investigators, while investigators ensure ethical conduct of the trial and respect for subjects. Clinical research associates support investigators and sponsors in carrying out clinical trials.
This document discusses concepts of in-vitro screening as an alternative to animal testing. It describes some of the major alternatives like cell culture techniques and computer simulation that aim to replace, reduce or refine animal testing. Specifically, it provides examples of how cell cultures have been developed as alternatives for tasks like monoclonal antibody production and toxicity testing. It also discusses the "Three Rs" framework of replacing, reducing and refining animal use in testing.
This document discusses translational pharmacology, which aims to translate biomedical research findings into improved patient care and treatment. It involves applying laboratory research to clinical practice through a "bench to bedside" approach. The objectives of translational pharmacology are to discover disease origins and biomarkers, and develop new diagnostics and therapies more quickly. While powerful tools now exist, hurdles remain, including scientific, ethical, regulatory, financial and lack of investigators. Translational pharmacology seeks to bridge specialized fields and provide better pre-clinical results and dosing regimens to maximize patient benefit.
Peptic ulcer disease and GERD are common digestive disorders caused by an imbalance between gastric acid and the stomach's protective mechanisms. Peptic ulcers form when the stomach or duodenal lining is broken down, typically due to H. pylori infection or long-term NSAID use. GERD occurs when stomach acid backs up into the esophagus, often due to a weak lower esophageal sphincter. Both are treated using proton pump inhibitors to reduce acid production along with antibiotics for H. pylori if present. Lifestyle changes like sleeping upright and smaller meals can help prevent acid reflux.
Cell lines are permanently established cell cultures that can proliferate indefinitely. They are derived from primary cell cultures which have a finite lifespan. Continuous cell lines have undergone transformation to proliferate indefinitely, unlike finite primary cultures. Common types of cell lines include normal and transformed cell lines of epithelial, fibroblast, or lymphoblast morphology derived from human or animal tissues. Primary cultures are used to establish cell lines which are then used for applications like drug screening, toxicity testing, and cancer research.
This document outlines the phases of clinical trials, from Phase 0 to Phase IV. It defines clinical trials as prospective biomedical studies on human subjects to answer questions about interventions. The objectives are listed as diagnosing or treating disease, preventing disease or early death, or changing behaviors. The phases are described in order from exploratory studies in small groups in Phase 0 to post-marketing surveillance trials in large populations in Phase IV. The importance of clinical trials is that they follow strict scientific standards to protect patients and produce reliable results, as a final stage of research after laboratory and animal testing.
This document discusses high throughput screening and cell-based assays. It begins by defining high throughput screening as a process used in drug discovery to quickly assay a large number of compounds against a biological target to identify hits or leads. It then describes some key aspects of high throughput screening methodology including detection methods like spectroscopy, chromatography, and microscopy. The document outlines the advantages of cell-based assays compared to biochemical assays, noting they provide a more accurate representation using live cells. Finally, it defines the key elements of a cell-based assay as having a cellular component, a target molecule, an instrument, and informatics for data analysis.
1. JAKTA
UDRUZENJE PRIREDJIVACA IGARA NA SRECU, OVLASCENIH
SERVISERA I PROIZVODJACA APARATA ZA IGRE NA SRECU
ASSOCIATION OF GAMING ORGANIZERS, AUTHORIZED
SERVICERS AND PRODUCERS OF GAMING EQUIPMENT
22.Decembar 2008.
3. Ciljevi za 2009. godinu
Obezbedjivanje sto boljih uslova za
rad
Podizanje standarda
Zajednicko delovanje sa vladom i
drugim organizacijama i
kompanijama, sinergija sa
ministarstvima kako bi gradjani
Srbije ucestvovali u igrama na
srecu prevashodno iz zabave
4. JAKTA
Stvara prijateljsko poslovno
okruzenje
Pomaze u uspostavljanju
dvosmernog podrzavanja zakona
Pronalazi puteve kako da se
industrija igara u legalnoj formi
integrise u savremeno drustvo